IMS 2024 | Diagnostic criteria for Castleman disease & the development of a novel symptom score
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the diagnostic criteria for idiopathic multicentric Castleman disease (iMCD), emphasizing the recent improvements in diagnosing this rare condition. Dr Ramasamy explains the development of a symptom score, which involves collaboration with patient partners to assess symptom reduction during treatment, moving beyond reliance on scans and blood tests. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Castleman disease, particularly of the idiopathic multicentric variety, has been recently approved a diagnostic consensus criteria. This has improved more diagnosis of this rare patient population. This patient group have a significant number of symptoms which are multiple different organ function related and because of the delayed diagnosis, these patients, when they’re first diagnosed conclusively, have a multi-morbid clinical presentation...
Castleman disease, particularly of the idiopathic multicentric variety, has been recently approved a diagnostic consensus criteria. This has improved more diagnosis of this rare patient population. This patient group have a significant number of symptoms which are multiple different organ function related and because of the delayed diagnosis, these patients, when they’re first diagnosed conclusively, have a multi-morbid clinical presentation. We, in conjunction with a number of academic investigators, are looking at developing a symptom score that can help categorize how patients are, not just at diagnosis, but also when they go through a treatment phase, that we can reliably show that their symptoms are reducing rather than purely basing our response on scans and on blood tests. This is being done with patients themselves. So a number of patient partners are involved in the development process and this is done in three stages and we’ve set out in this poster as to how this is being done.
Read more...
